Alembic Pharmaceuticals has announced that its Board of Directors will convene on Tuesday, November 4, 2025, to review and approve the unaudited financial results for the quarter and half-year ending September 30, 2025. The trading window for company securities, previously closed on October 1, 2025, will reopen 48 hours after the financial results are declared.
Board Meeting Announcement
Alembic Pharmaceuticals is set to hold a meeting of its Board of Directors to discuss and approve the company’s unaudited financial results. The meeting is scheduled for Tuesday, November 4, 2025.
Financial Results Consideration
During the meeting, the board will primarily focus on reviewing and approving the unaudited financial results for the quarter and half-year which concluded on September 30, 2025.
Trading Window Update
The company has also announced an update regarding the trading window for designated persons and their immediate relatives. The window, which was closed starting October 1, 2025, will be re-opened 48 hours following the official declaration of the financial results. This ensures compliance and prevents any potential insider trading activities before the results are made public.
Source: BSE
